Comments for Dr. Karen Lee's Blog https://drkarenlee.ca An Inside Look at MS Research Sat, 02 Jun 2018 05:59:16 +0000 hourly 1 https://wordpress.org/?v=4.6.11 Comment on MS Society of Canada poised to feature research and researchers for May Awareness Month and World MS Day by Stacystone https://drkarenlee.ca/ms-society-of-canada-poised-to-feature-research-and-researchers-for-may-awareness-month-and-world-ms-day/#comment-606 Sat, 02 Jun 2018 05:59:16 +0000 https://drkarenlee.ca/?p=1742#comment-606 I am a regular follower of your blog. And the points you have mentioned over here are very essential in my point of view.

]]>
Comment on Incidence and Prevalence: What do they mean, how new numbers are identified and why they are important? by drkarenlee https://drkarenlee.ca/incidence-and-prevalence-what-do-they-mean-how-new-numbers-are-identified-and-why-they-are-important/#comment-605 Fri, 01 Jun 2018 13:12:25 +0000 https://drkarenlee.ca/?p=1809#comment-605 Hi Jonathan,

Thanks for the feedback.

In response to your questions, here are my answers:

1. This data was previously reported based on several surveys that were developed through the National Population Health Study of Neurological Conditions to estimate the incidence and prevalence rates of MS in households and long-term care facilities. One of the surveys, the 2010-2011 Canadian Community Health Survey (CCHS), asked respondents if they, or members of their household had any one of 18 neurological conditions including MS. With this type of questionnaire, it is possible households over-reported MS (e.g. not diagnosed with MS but going through tests for potential MS).

2. The statistics are updated from what was previously reported in 2010-2011 using the national surveys. CCDSS identified the incidence and prevalence rates of MS using validated data from health care visits, allowing the CCDSS to utilize a more reliable method to determine the national estimates of MS in the adult Canadian population.It takes a few years for the PHAC to be able to gather information from all provinces and territories, analyze the data and then report the statistics. Moving forward, PHAC’s goal is to update these numbers on a more regular basis.

3. These statistics are very important for Canadians living with MS. These fundamental numbers form the basis for identifying the needs of people living with MS as well as the risk of developing MS. If there is a recognition that the number of Canadians living with MS is increasing, which it is based on these new statistics, then it will be important information that speaks to the need for more resources in the Canadian healthcare system, changes in policies and more programs to support this increasing population. Also, the if the incidence rates are increasing, which they are not, it would inform us for the need to look at changes in risk factors in the population. Knowing what the risk factors are for MS can then help is in our journey to find a cure.

For more information, you can also check out the MS Update.

-Dr. K

]]>
Comment on Incidence and Prevalence: What do they mean, how new numbers are identified and why they are important? by Jonathan Allenger https://drkarenlee.ca/incidence-and-prevalence-what-do-they-mean-how-new-numbers-are-identified-and-why-they-are-important/#comment-604 Fri, 01 Jun 2018 02:13:17 +0000 https://drkarenlee.ca/?p=1809#comment-604 Karen,

Great post and thank you for the updated incidents and prevalence statistics for MS in Canada. A few follow up questions for you:
1) What methodology was previously used to determine the previously quoted incidence and prevalence rates for MS in Canada?
2) Why are we talking about updated statistics in 2018 that are from 3-4 years ago (2014-15)?
3) What do the changes in these statistics mean for Canadians impacted by MS?

Jonathan

]]>
Comment on Getting personal with a promising treatment approach to MS by drkarenlee https://drkarenlee.ca/getting-personal-with-a-promising-treatment-approach-to-ms/#comment-601 Thu, 24 May 2018 13:56:50 +0000 https://drkarenlee.ca/?p=1430#comment-601 Hi Marc,

For information on participating in this treatment, please visit the Ottawa Hospital Research Institute website here.

-Dr. K

]]>
Comment on Faces Behind the Science: Evelyn Peelen by Martin Matko https://drkarenlee.ca/faces-behind-the-science-evelyn-peelen/#comment-599 Tue, 15 May 2018 07:18:55 +0000 https://drkarenlee.ca/?p=1789#comment-599 Eliminating cause Symptoms of so called Multiple Sclerosis will End MS often when CCSVI is treated w/Venous Angioplasty SymptoMS often Ease/Disappear incl Fatigue, sleep apnea, gait, cognition urinary issues, ect Ect ECT! FACILITATE AND MAKE AVAILABLE CCSVI TREATMENT RESEARCH!!!!

]]>
Comment on American Academy of Neurology: Multiple Sclerosis risk factors and susceptibility by Jim Eddington https://drkarenlee.ca/american-academy-of-neurology-multiple-sclerosis-risk-factors-and-susceptibility/#comment-598 Wed, 09 May 2018 22:23:59 +0000 https://drkarenlee.ca/?p=1777#comment-598 We don/t how we got it .but we sure like to get something for the symptoms

]]>
Comment on Faces behind the science: Nathan Michaels by Michael Crowell https://drkarenlee.ca/faces-behind-the-science-nathan-michaels/#comment-596 Sun, 06 May 2018 00:18:05 +0000 https://drkarenlee.ca/?p=1747#comment-596 Thank you all from the bottom of my heart for what you do. Each and every one of you are special. Our daughter who is a DDS was diagnosed with MS in July 2017. God bless you all. I am forever grateful for your research.

]]>
Comment on American Academy of Neurology: A new biomarker to monitor disease progression and treatment response in MS by Julia https://drkarenlee.ca/american-academy-of-neurology-a-new-biomarker-to-monitor-disease-progression-and-treatment-response-in-ms/#comment-595 Sat, 28 Apr 2018 01:01:32 +0000 https://drkarenlee.ca/?p=1732#comment-595 Thanks

]]>
Comment on American Academy of Neurology: A new biomarker to monitor disease progression and treatment response in MS by drkarenlee https://drkarenlee.ca/american-academy-of-neurology-a-new-biomarker-to-monitor-disease-progression-and-treatment-response-in-ms/#comment-594 Fri, 27 Apr 2018 18:20:56 +0000 https://drkarenlee.ca/?p=1732#comment-594 Dear Ian,
The technique to detect neurofilament in the blood serum is still in its early phase as there is still the need to standardize this technique. Standardization will eventually allow clinicians to use the same reference value for the level of neurofilament and the results won’t be interpreted in an arbitrary way. Nonetheless, the results are very encouraging as the levels of neurofilament seems to reflect brain activity.

-Dr. K

]]>
Comment on American Academy of Neurology: A new biomarker to monitor disease progression and treatment response in MS by drkarenlee https://drkarenlee.ca/american-academy-of-neurology-a-new-biomarker-to-monitor-disease-progression-and-treatment-response-in-ms/#comment-593 Fri, 27 Apr 2018 18:19:43 +0000 https://drkarenlee.ca/?p=1732#comment-593 Dear Julia,

The samples were collected either via lumbar puncture to obtain cerebrospinal fluid, or via blood withdrawal to collect the serum. Surely, the lumbar puncture is more invasive than taking blood, which is a routine procedure. Analyzing the two body fluids, the researchers reported that the increased levels of neurofilament were in both the blood serum and cerebrospinal fluid. This suggests that the blood serum, less invasive to collect, is appropriate for this type of analyses.

-Dr. K

]]>